Australia: Three strikes, you're out: Rosuvastatin generics in the clear

Last Updated: 8 September 2015
Article by Katrina Crooks and Nadia Pece-Barbara

The High Court of Australia handed down its decision yesterday in the appeal by AstraZeneca (AstraZeneca AB v Apotex Pty Ltd (2015) HCA 30), against last year's ruling by the Full Court of the Federal Court, affirming the Full Court's decision that AstraZeneca's low dose rosuvastatin patent was obvious.

The High Court has unanimously sided with the Full Court, finding that there was no error in its reasoning in applying the test for inventive step. In particular, the Full Court's construction of section 7(3) of the Patents Act 1990 (Cth) was affirmed.

The High Court side-stepped any decision on the 'starting point' approach, on the basis that it was not necessary to consider the issue in light of its finding on the construction of s7(3). This approach was previously adopted by an earlier Full Court in Apotex Pty Ltd v Sanofi-Aventis [2009] FCAFC 134 under the Patents Act 1952. It allowed information contained in the relevant patent specification, but which did not form part of the common general knowledge, to be taken into account in an obviousness analysis. In Rosuvastatin, the Full Court found that the 'starting point' approach is not applicable under the current Patents Act. As the High Court did not consider this issue, that decision now stands.


AstraZeneca appealed to the High Court after being unsuccessful both at first instance (Apotex v AstraZeneca (No 4)) and before the Full Federal Court (AstraZeneca AB v Apotex Pty Ltd [2014] 312 ALR 1). Although three patents were considered at first instance, and the appeal before the Full Court concerned two patents, the only patent in suit in the High Court appeal was AU 200023051 ("'051 Patent"). The '051 Patent claimed methods of treating a patient suffering from hypercholesterolemia comprising administration of 5 or 10 mg of the pharmaceutical compound, rosuvastatin (sold under the brand name CRESTOR) as a starting dose for the treatment of hypercholesterolemia.

The primary judge found the '051 Patent invalid on three grounds: lack of entitlement; lack of novelty in light of two prior art publications; and obviousness within the meaning of s 7(2) of the Act. The Full Court of the Federal Court of Australia overturned only the finding of lack of novelty and otherwise dismissed the appeals from the primary judge's decision.

Issues of interpretation of the Patents Act

The primary issue considered by the High Court was the meaning of ss 7(2) and 7(3) of the Patents Act. Subsection 7(2) requires inventive step to be assessed by reference to common general knowledge, considered separately or together with prior art information falling within s 7(3). The "threshold requirement" under s 7(3) is that the prior art information could, before the priority date of the relevant claim, be reasonably expected to have been ascertained, understood and regarded as relevant to work in the relevant art in Australia.

Importantly, under the Patents Act as it stood at the time relevant to the '051 Patent, s 7(3) only permitted combining documents which would be treated as a single source of information. Following amendments in 2001 this requirement was relaxed to allow combination of documents for obviousness purposes where the skilled person could be reasonably expected to do so. Mosaicing of prior art information which is not common general knowledge is not permitted unless this requirement is met.

The expert evidence in the case identified literature and patent searches which the experts carried out when posed with the problem of finding a more effective alternative statin. These searches led to the identification of the prior art information invoked against the '051 Patent, in particular the Watanabe article. This article disclosed the compound rosuvastatin and the fact that it was in clinical trials. However the experts also identified another document, the Aoki article, which disclosed another promising compound.

AstraZeneca asserted firstly that in identifying the Watanabe article as relevant for the purposes of s7(3), the experts had had regard to other prior art publications disclosed by their searches, by way of a process of comparison. AstraZeneca argued that a process of satisfying the 'regarded as relevant' requirement of s 7(3) which involves comparing various non-"cgk" publications, amounted to the impermissible combining of such documents for the purpose of s7(3).

Secondly, it argued that the Full Court had taken a "single avenue approach". By this it argued that, having identified the Watanabe article as ascertained and relevant, the Full Court had decided the question of inventive step on the basis that the only course available to the skilled person was the course identified in that document i.e. the use of rosuvastatin. In light of the existence of the Aoki article, it argued that it had not been shown that the skilled person would have chosen rosuvastatin rather than the other promising new compound identified in Aoki.

The High Court Judgment

The High Court had no difficulty in finding that there was no impermissible combination of documents in order to find the Watanabe article relevant. The words "considered separately" in s7(2) qualify the way in which prior art information complying with s 7(3) must be used, but they say nothing about how the relevance requirement of s7(3) is to be satisfied. Accordingly, the finding of Jessup J in the Full Court was correct: it was wholly within the scheme of the subsection that the skilled person might well sort through all manner of information with a view to finding something that is regarded as relevant.

On the second argument, AstraZeneca seemed destined to fail in light of the evidence of at least one of the expert witnesses that he would have selected rosuvastatin as the most promising candidate, on the basis that the Watanabe article suggested that it had high potency with reduced side-effects and it had progressed to clinical trials.

However this begs the question of what the position might be in a situation where a document falling within s 7(3), considered alone, would directly lead the skilled person to the invention, but where there might be other documents (also falling within s 7(3)) which might lead the skilled person in a different direction.

French CJ considered that it sufficed to say that the text of s7(2) "simply did not offer a constructional choice imposing the limitation for which AstraZeneca contends", that is, the limitation that the Court was not permitted to decide the question of obviousness on the basis that the only course available to the skilled person was that identified in the relevant s7(3) document.

Gageler and Keane JJ considered that (at paragraph [115]):

"Section 7(2) does not contemplate that a choice between apparently effective solutions must be attributed to the notional skilled addressee, much less that the notional skilled addressee might be so befuddled by an embarrassment of choices as to cease pursuit of the solution."

While understandable as a construction of ss 7(2) and (3) (as they stood at the relevant time for this case), it does appear that this construction could lead to an obviousness analysis, divorced from the actual reality that in order to arrive at an invention the skilled person may be required to choose between a number of promising options. On the High Court's reasoning it appears that a s 7(3) document could form the basis for an obviousness finding, even if the expert gave evidence that they would, in practice, have preferred a different solution contained in another s7(3) document.

Interestingly Kiefel J acknowledged that it was necessary for the expert to select the best candidate because the clinical trials which would follow are extremely expensive. However since this comparison was not done with a view to determining the relevance of each document per se, it could not affect the relevance of any given document under s7(3).

A possible alternative construction of s7(3) could perhaps arise under the Patents Act as it now stands (both pre- and post- Raising the Bar). As mentioned above, s7(3) now permits combination of two or more pieces of s7(3) information, where the skilled person could be reasonably expected to do so. A more restrictive version of s7(3) was in place at the relevant time of this case. Arguably, when confronted with two documents pointing to two different, and both potentially useful, compounds, it might be said that the skilled person could reasonably be expected to combine the information in both documents to reach a decision as to which path to take.

It is important to note that post – the Raising the Bar amendments, the requirement that relevant prior art information could reasonably have been ascertained, understood and regarded as relevant has been removed from s 7(3). As a result, any publically available information can be taken into account under s 7(3). Applying the High Court's reasoning, this would appear to open the door even further for argument that if any one document considered on its own (even if not likely to be ascertained by the skilled addressee) would directly lead the skilled addressee to the invention, the invention will be obvious. That conclusion could be reached regardless of whether the skilled person would likely, in reality, choose a different path.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Katrina Crooks
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.